Knee and joint pain used to leave two options — medication or surgery. Today a middle path exists. This guide walks through every regenerative option in plain language, with the research behind each, so you can make an informed choice.
Steroid injection combined with hyaluronic acid
What it is: A steroid (anti-inflammatory) combined with hyaluronic acid, injected directly into the joint.
How it works: The steroid rapidly switches off inflammation. The HA adds a small amount of lubrication to the joint.
Corticosteroid injections reliably reduce pain in the short term — typically weeks to a few months. Comparative trials consistently show PRP produces better long-term outcomes than corticosteroids in knee OA. Repeated steroid use is avoided long-term due to concerns about cumulative effects on joint tissue.
Best suited for: Acute flare-ups, or patients who need quick relief for a specific event — not a long-term joint-preservation strategy.
Viscosupplementation — restoring joint fluid
What it is: A gel-like substance that mimics the natural fluid inside a healthy joint.
How it works: HA restores some of the cushioning and lubrication that thins out as cartilage wears down.
HA has decades of use in knee OA. Generally safe and modestly effective for symptom relief. Multiple comparative studies now show PRP combined with HA outperforms PRP alone, and that biologic therapies tend to outlast HA on pain and function scores at 6-12 months. This is why HA is most valuable today as an add-on to biologic therapy rather than a standalone long-term solution.
Best suited for: Mild osteoarthritis, or as the maintenance component of a PRP / GFC course.
Your own platelets and growth factors — most researched orthobiologic
What it is: A concentrate of your own platelets and growth factors, spun down from a small blood draw.
How it works: Platelets release growth factors that reduce inflammation and support the joint's own repair processes.
PRP is one of the most researched orthobiologics available. A 2025 review of 40 studies found leukocyte-poor PRP shows superior pain relief and functional improvement compared to hyaluronic acid and corticosteroids, particularly in mild-to-moderate knee OA. A meta-analysis of 11 randomized trials with 1,616 patients found a statistically significant reduction in pain scores favoring PRP over placebo at three months. Multiple systematic reviews confirm PRP outperforms both corticosteroids and hyaluronic acid on pain and function, especially over the longer term.
Best suited for: Early-to-moderate OA, tendon injuries, and patients wanting a well-evidenced, low-risk biologic option.
Autologous growth factors — distinct profile from PRP
What it is: A concentrated preparation of your own growth factors derived from peripheral blood — mechanistically related to PRP but prepared differently with a distinct growth factor profile.
How it works: Similar to PRP — delivering a concentrated dose of the body's own repair signals directly into the joint.
A placebo-controlled randomized trial found three monthly GFC injections produced clinically meaningful, statistically significant improvements in pain and function sustained through 12 months in Grade II-III knee OA. GFC also significantly reduced blood levels of a cartilage-degradation marker. A more recent randomized trial suggested GFC may act as a disease-modifying therapy rather than purely symptomatic — with particular benefit in early-to-moderate OA.
Best suited for: Early-to-moderate knee OA (Grade II-III), typically delivered as a 3-session course.
How PRP and GFC are structured into evidence-based courses
PRP and GFC are typically delivered as a 3-session course, not a single shot — the research reflects serial dosing, not one-off injections. Three tiers depending on protocol intensity:
All 3 sessions combine PRP or GFC with HA. Meta-analysis confirms combining PRP with HA outperforms PRP alone on pain and function scores.
Session 1 uses most concentrated biologic signalling protocol. Sessions 2 and 3 continue on the Plus protocol.
All 3 sessions use the most concentrated protocol throughout — for patients wanting the fullest course of biologic signalling support.
These tiers reflect dose and protocol intensity, not different drugs — the underlying base (PRP or GFC) is the same throughout a course.
Fat-derived stromal cells — treats both knees in one sitting
What it is: A small amount of your own fat tissue, gently processed into microfragmented form rich in stromal and progenitor cells, then injected into the joint.
How it works: Adipose tissue is one of the richest natural sources of mesenchymal stromal cells in the body. Microfragmentation preserves the tissue's natural stromal-vascular niche while making it injectable.
A 2024 randomized controlled trial comparing mFAT to corticosteroid and saline found mFAT provided meaningful pain relief and improved joint function over a full year of follow-up — positioning it as a viable option for patients who fall between conservative care and surgery. A separate RCT combining mFAT with arthroscopic debridement found improved functional outcomes and MRI cartilage appearance compared to debridement alone.
Best suited for: Moderate-to-severe bilateral OA, or patients wanting an autologous cellular option without a bone marrow harvest. Because harvesting is a one-time outpatient procedure, mFAT can treat both knees in the same sitting.
Bone marrow stem cells — longest follow-up data available
What it is: Concentrated mesenchymal stem cells and growth factors drawn from your own bone marrow (usually the pelvic bone) and injected into the joint.
How it works: Bone marrow is a well-established source of mesenchymal stromal cells, which have anti-inflammatory and tissue-supportive effects.
A four-year follow-up study — one of the longest available for any regenerative treatment — found BMAC produced significant improvement in function compared to hyaluronic acid and PRP. A randomized trial comparing a single BMAC injection against three weekly HA injections found BMAC was statistically superior on pain scores at both 6 and 12 months. A meta-analysis of 10 studies and 472 patients found BMAC produced a large, significant reduction in pain — VAS scores dropping from a mean of 5.8 to 2.6.
Best suited for: Moderate-to-severe OA where a patient wants the depth of evidence behind bone-marrow-derived stem cells, or where mFAT is not the preferred source. Can treat both knees in one sitting.
Donor-derived cells — off-the-shelf standardised product
What it is: A donor-derived (not the patient's own) stem cell preparation — used where a patient's own tissue may not be an ideal source, or a standardised cell product is preferred.
How it works: Allogeneic MSCs are manufactured from screened donor tissue, expanded in controlled lab conditions, and injected into the joint — offering a consistent, standardised cell dose rather than one dependent on the patient's own cell yield.
A landmark randomized controlled trial comparing allogeneic bone marrow MSCs to HA found the allogeneic MSC group had significant pain relief and significantly improved cartilage quality. A Phase I/IIa randomized placebo-controlled trial of an allogeneic adipose-derived MSC product found a greater proportion of treatment responders than placebo with clinically and statistically significant improvement in pain and all functional sub-scores. A systematic review of randomized trials concluded the safety profile of allogeneic MSCs is excellent, with adverse events largely limited to minor injection-site reactions.
Best suited for: Patients who prefer not to undergo a personal tissue harvest, or where a standardised, quality-controlled cell product is preferred. Typically administered per joint (one knee per sitting).
| Therapy | Source | Sessions | Best For | Evidence |
|---|---|---|---|---|
| Corticosteroid + HA | N/A | 1 | Fast short-term flare relief | Strong (short-term) |
| Hyaluronic Acid | N/A | 1 or add-on | Mild OA, maintenance sessions | Strong (modest effect) |
| PRP | Your blood | 1-3 | Early-moderate OA, tendon injury | Strong — extensive RCT |
| GFC | Your blood | 3 (course) | Early-moderate OA (Grade II-III) | Growing — positive RCT |
| mFAT | Your fat | 1 (both knees) | Moderate-severe bilateral OA | Promising — RCT supported |
| BMAC | Your bone marrow | 1 (both knees) | Moderate-severe OA | Strong — 4-year follow-up |
| Allogeneic Stem Cell | Donor-derived | 1 (one knee) | Standardised cellular option | Promising — Phase I/II RCT |
Regenerative orthobiologics are an active, fast-moving research area. Most therapies above have strong RCT support for pain and function improvement, particularly in mild-to-moderate osteoarthritis. Evidence for disease modification — actually slowing or reversing joint damage rather than just relieving symptoms — is more preliminary and still developing across all these therapies. Your suitability for any of these depends on your OA grade, joint condition, and overall health, and is best assessed in a consultation with Dr. Sumit.
"I do not offer regenerative treatment to every patient who walks in. I offer it to the patients it will genuinely help, after honest assessment of their OA grade and joint condition. And I am equally honest when surgery is the better answer. The options above represent a genuine spectrum from simple to advanced — the right choice depends on where you are on that spectrum, not on which treatment sounds most impressive."
— Dr. Sumit Dubewar · DABRM (USA) · Secunderabad
Book a consultation with Dr. Sumit. Bring your X-ray and MRI. He will assess your OA grade, explain all options honestly, and give you a clear recommendation.
Book Consultation WhatsApp